Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma
AKR1B1-driven #MetabolicReprogramming sustains #DrugResistance in #HCC, while #epalrestat restores sensitivity—positioning AKR1B1 as both #biomarker and therapeutic target to overcome systemic resistance. @tsinghuauniversity.bsky.social
#STTT: doi.org/10.1038/s413...